An expert explores factors influencing the selection of treatment regimens in relapsed, triple class refractory multiple myeloma (MM) patients, with a focus on prophylactic measures for managing adverse events associated with novel agents like Selinexor, bispecific, and CAR-T therapies.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.